Curriculum Vitae

Name	**Lillian L. Siu, MD**	
Current Position & Affiliation	**Professor,** **University of Toronto** **Medical Oncologist,** **Princess Margaret Cancer Centre** **Director,** **Phase I Program** **BMO Financial Group Chair in Precision Genomics**	
Country	**Canada**	

Educational Background

1994-1996	Fellowship, Medical Oncology, Faculty of Medicine, University of Toronto
1996-1997	Canadian Association of Medical Oncology Fellowship in Oncopharmacology, Princess Margaret Cancer Centre, University of Toronto
1997-1998	Fellowship in New Drug Development, University of Texas Science Centre at San Antonio

Professional Experience

1998-present	Full-time Active Staff Medical Oncologist, Division of Medical Oncology/Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network
1998-2004	Assistant Professor, Faculty of Medicine, University of Toronto
2001-present	Co-Director of Robert and Maggie Bras and Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network
2001-present	Director of Phase I Program, Princess Margaret Cancer Centre, University Health Network
2001-2014	Director of Drug Development Fellowship Program, Princess Margaret Cancer Centre, University Health Network
2004-2009	Associate Professor, Faculty of Medicine, University of Toronto
2009-present	Full Professor, Faculty of Medicine, University of Toronto

2012-present Director, Cancer Genomics Program, Princess Margaret Cancer Centre, University Health Network
2015-present Co-Clinical Leader, Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network
2016-2026 BMO Chair in Precision Cancer Genomics

Professional Organizations

International Committees:

2011-2012 Chairperson: AACR Educational Committee
2011-2012 Co-Chairperson: AACR Scientific Committee
2012-2014 Co-Chair: Investigational Drug Steering Committee, Cancer Therapy Evaluation Program, US National Cancer Institute
2012-2016 Member: ASCO Board of Directors

2013-2015 Chair: ASCO Long-Term Fellowship (LIFe) Award Committee
2013-2015 Co-Chair: Investigational Drug Steering Committee, NCI Cancer Therapy Evaluation Program
2013-2015 Chairperson: Landon Foundation-AACR Innovator Award for International Collaboration in Cancer Research Scientific Review Committee
2013-2016 Member: AACR Women in Cancer Research Council
2013 Reviewer: National Cancer Institute National Clinical Trials Network (NCTN)
2014-2016 Member: AACR Nominating Committee
2014- Member: External Scientific Advisory Board, Worldwide Innovative Networking (WIN) Consortium
2014-2016 ASCO: Mentor, Leadership Development Program
2016-2020 Co-Chair: ASCO Head and Neck Cancers Guideline Advisory Group
2017-2020 Member: AACR Board of Directors

Awards:

2010 NCI Michaele C. Christian Oncology Development Award
2011 Teaching Award, Division of Medical Oncology, Faculty of Medicine, University of Toronto
2011 Elise Winifred Crann Memorial Trust Award in Medical Research, Faculty of Medicine, University of Toronto
2013 Wightman-Berris Award for Individual Teaching Excellence, Department of Medicine, Faculty of Medicine, University of Toronto
2016 Eaton Scholar of the Year, Department of Medicine, University of Toronto

2017-2018 Michael Hutcheon Mentor Award, Department of Medicine, University of Toronto
2020 TAT Honorary Award Recipient
2020 International Women Who Conquer Cancer Mentorship Award

Main Scientific Publications

https://www.ncbi.nlm.nih.gov/myncbi/lillian.siu.1/bibliography/public/

1. **Experimental Therapeutics and Phase I Clinical Trials, including Immuno-Oncology:** I have been focused in the field of experimental therapies to understand how best to bring novel anticancer agents from preclinical testing to first-in-human evaluation. I have been involved in numerous phase I clinical trials investigating molecularly targeted agents, novel cytotoxics and more recently immunotherapeutics such as immune checkpoint inhibitors, immuno-oncology combinations. I have familiarity with many biological classes of agents, their mechanisms of action, biomarkers of response or resistance, as well as their on-target and off-target toxicity profiles.
    a. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, **Siu LL.** Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012 May 1;30(13):1527-33. doi: 10.1200/JCO.2011.38.9346. Epub 2012 Mar 26. PMID: 22454420.
    b. Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, **Siu LL.** An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0. PMID: 30867072; PMCID: PMC6417194.
2. **Clinical Trials Methodology:** I have a keen interest in the area of clinical trials methodology, especially in the design and conduct of phase I trials. I have published original work and reviews focusing on choice of starting dose, dose escalation methods, use of expansion cohorts, late toxicity assessments, prognostic index, etc. in phase I trials. These initiatives have been done either through research projects with junior investigators whom I have mentored, or via international collaborations such as the DLT-TARGETT and MD-ICT groups.

a. Cescon D, **Siu LL**. Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. Cell. 2017 Feb 9;168(4):575-578. doi: 10.1016/j.cell.2017.01.027. PubMed PMID: 28187280.
b. **Siu LL, I**vy SP, Dixon EL, Gravell AE, Reeves SA, Rosner GL. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. Clin Cancer Res. 2017 Sep 1;23(17):4950-4958. doi: 10.1158/1078-0432.CCR-16-3079. PMID: 28864723; PMCID: PMC5669041.
c. Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, **Siu LL,** Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196. PMID: 30561713; PMCID: PMC6376915.

3. **Head and Neck Cancer:** My disease specific focus is in the area of head and neck cancer. I have been involved in the development of novel agents such as inhibitors of epidermal growth factor receptors (e.g. erlotinib, dacomitinib, etc) in recurrent or metastatic squamous cell cancers of the head and neck (RM-SCCHN). More recently, I have been actively engaged in clinical trials of immune checkpoint inhibitors in this disease. For example, I was the global principal investigator of the CONDOR trial (below).
   a. **Siu LL,** Waldron JN, Chen BE, Winquist E, et al. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2016 Dec 8. doi: 10.1001/jamaoncol.2016.4510. [Epub ahead of print] PubMed PMID: 27930762.
   b. Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, Hope AJ, Cho J, Razak AA, Hansen A, Jang R, Perez-Ordonez B, Weinreb I, Bossi P, Orlandi E, Licitra LF, Song Y, O'Sullivan B, **Siu LL**, Kim J. Impact of cisplatin dose intensity on human papillomavirus-related and –unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer. 2016 Nov;67:174-182. doi: 10.1016/j.ejca.2016.08.013. Epub 2016 Sep 24. PubMed PMID: 27669504.
   c. **Siu LL,** Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2018 Nov 1. doi: 10.1001/jamaoncol.2018.4628. [Epub ahead of print] PubMed PMID: 30383184.

a. **Liquid Biopsy Related Research:** Along with Drs. Bratman, De Carvalho and Pugh, I have been actively involved in several investigator-initiated studies that evaluate the role of liquid biopsies as prognostic and predictive biomarkers for immunotherapeutics.
    a. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, **Siu LL**, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;30(10):1580-1590.
    b. Cescon DW, Bratman S, Chan S, **Siu LL.** Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1:276-90.
    c. Bratman S, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Abdul Razak, A, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi S, Aleshin A, Torti D, Marsh K, Eagles J, Cirlano I, Hanna Y, Cloutheir DL, Lien SC, Ohashi PS, Xu W, **Siu LL,** Pugh TJ. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treatment with pembrolizumab. Nat Cancer. 2020.